CSL Behring, a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products, agreed to acquire Vitaeris, a clinical-stage biotechnology company. Financial terms were not disclosed. "Clazakizumab has been a promising monoclonal antibody in the Transplant therapeutic area since we started working with Vitaeris several years ago. Acquiring Vitaeris and their associate expertise helps us to continue to grow our strategic scientific platform of recombinant proteins and antibodies. We look forward to continuing to advance this treatment candidate as a potential option for people experiencing rejection – an area where current treatment options for transplant recipients are limited, at best," Bill Mezzanotte, CSL Behring Executive Vice President, Head of R&D.